

Like 1,545 people like this. [Sign Up](#) to see what your friends like.



**Chairman: Dr.PUKHRAJ RISHI**  
**Co-Chairman: Dr.KAUSTUBH MULAY**  
**Convenor: Dr.DIPANKAR DAS**  
**Moderator: Dr.BHAVNA CHAWLA**

**SECTION : OCULAR PATHOLOGY**

**DATE: 26.02.2016 HALL: L TIME: 14:00 - 15:25**

**FREE PAPER 1 [FP1193]**

**INTRAVITREAL TOPOTECAN INJECTION AS MONOTHERAPY FOR REFRACTORY VITREOUS SEEDS IN RETINOBLASTOMA**

CHIEF AUTHOR : .DR. RAKSHA RAO, PRESENTING AUTHOR : R17558 - .DR. RAKSHA RAO , CO-AUTHORS : DR.VISHALSHARMA, DR.SANTOSH G HONAVAR, DR.VIJAY ANAND P REDDY, - BANGALORE

Purpose: To evaluate the safety and efficacy of intravitreal topotecan (IViT) for the management of refractory vitreous seeds in retinoblastoma. Methods: Intravitreal Topotecan injection (30 µg in 0.15 mL) was provided by the safety-enhanced technique. Results: Twenty two eyes received a mean of 3 (range 2-6) 3-weekly intravitreal Topotecan injections. Prior treatment included chemotherapy in all, periocular carboplatin in 12, and intravitreal melphalan in 3. Complete regression of vitreous seeds was achieved in 21 of 22 (95.5%) eyes at a median follow-up of 12 months. One eye (4.5%) with a recurrent retinal tumor needed enucleation. Histopathology of the eye showed no tumor cells in the needle track. No ocular or systemic complication was observed. Visual acuity remained stable or improved in all. Conclusion: Spaced-out three-weekly intravitreal Topotecan injection as monotherapy for refractory vitreous seeds in retinoblastoma appears safe and potent.

Like 1,545 people like this. [Sign Up](#) to see what your friends like.

**Who else is attending**

